Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.65 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4131416 | 0.84 | PTGDR2 (0.71) | PTGDR2LMNASMN1; SMN2GFERNPSR1 | |
| SCHEMBL4134449 | 0.81 | P2RY1 (0.61) | P2RY1LMNASMN1; SMN2 | |
| SCHEMBL4134452 | 0.81 | P2RY1 (0.61) | P2RY1LMNASMN1; SMN2 | |
| SCHEMBL5503688 | 0.81 | PTGDR2 (0.50) | PTGDR2P2RY1LMNASMN1; SMN2 | |
| SCHEMBL27322991 | 0.81 | PTGDR2 (0.55) | PTGDR2P2RY1MEN1KMT2A | |
| SCHEMBL5397091 | 0.79 | PTGDR2 (1.00) | PTGDR2LMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL5404990 | 0.79 | PTGDR2 (1.00) | PTGDR2LMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL4123966 | 0.78 | PTGDR2 (0.79) | PTGDR2LMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL4136680 | 0.77 | PTGDR2 (0.62) | PTGDR2LMNASMN1; SMN2GFERNPSR1 | |
| SCHEMBL4130883 | 0.76 | PTGDR2 (0.71) | PTGDR2LMNASMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090181966-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-07-16 | — | — | US | disclosed |
| US-7504508-B2 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-20050256158-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256158-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | PTGDR2, LTB4R2, CYSLTR2 | PTGDR2 1/4885P2RY1 387/4885LMNA 4545/4885 |
| US-20090181966-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | PTGDR2, LTB4R2, CYSLTR2 | PTGDR2 1/4885P2RY1 387/4885LMNA 4545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.